Hanmi Pharmaceuticals [128940] showed weakness in intraday trading on the 25th despite a positive assessment from a securities firm. That day, Hanmi Pharmaceuticals traded at 514,000 won, down 4.81% from the previous trading day, as short-term profit-taking and supply-demand pressures weighed on the stock price.

On the 25th, Mirae Asset Securities released a report titled 'The Weapon to Catch Lilly and Novo, Roche Finds It at Hanmi,' presenting an investment opinion of 'Buy' and a target price of 730,000 won for Hanmi Pharmaceuticals. As the report title suggests, Mirae Asset Securities appears to have evaluated Hanmi Pharmaceuticals' platform and pipeline competitiveness in the global obesity and metabolic disease treatment market, as well as the possibility of collaboration with Roche, as key investment points.

The obesity treatment market is currently led by Eli Lilly and Novo Nordisk. However, as global pharmaceutical companies actively move to secure next-generation obesity and metabolic disease treatments, competition for technology transfers and joint development is also intensifying. Hanmi Pharmaceuticals has developed new drug candidates in the fields of obesity and metabolic diseases based on its proprietary platform technology, and as such, whether it expands collaboration with global pharmaceutical companies is cited as a key variable that will determine its future corporate value.

The stock price moved in the opposite direction of the securities firm's positive outlook that day. The target price of 730,000 won represents a considerable gap compared to the current stock price of 514,000 won. However, since the securities firm's target price is a forecast reflecting future performance, the value of the new drug pipeline, and the possibility of technology transfer, it may differ from short-term stock price direction.

Going forward, key points to watch for Hanmi Pharmaceuticals' stock price will include whether its collaboration with Roche actually leads to clinical development and contracts, and how the clinical progress speed and global competitiveness of its obesity and metabolic disease pipeline are confirmed.

[New drug development and technology transfers by pharmaceutical and biotech companies may vary depending on clinical results, regulatory reviews, contract terms, and development schedules. Target prices and investment opinions presented by securities firms are also forecasts based on certain assumptions and do not guarantee actual stock price increases. In particular, if expectations related to new drugs are already reflected in the stock price, volatility may expand depending on clinical results or contract progress, so investors should comprehensively check company disclosures, clinical progress, and performance. This article is not intended to recommend the purchase or sale of specific stocks or to guarantee investment returns. This article was written with AI assistance.]